Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer

Translational Oncology Research International

Status and phase

Completed

Phase 2

Conditions

Gastric Cancer

Esophageal Cancer

Treatments

Drug: everolimus

Other: laboratory biomarker analysis

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00985192

UCLA-TRIO-TORI-GI-06

CDR0000655574

IRB# 09-07-061-01

NOVARTIS-UCLA-TRIO-TORI-GI-06

Details and patient eligibility

About

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well everolimus works in treating patients with previously treated unresectable or metastatic esophageal cancer or stomach cancer.

Full description

OBJECTIVES:

Primary

To determine the overall disease-control rate (complete response, partial response, or stable disease) in patients with previously treated unresectable or metastatic adenocarcinoma of the upper gastrointestinal tract treated with everolimus.

Secondary

To determine the safety and toxicity of everolimus in these patients.
To determine the efficacy of everolimus, in terms of time to response, duration of response, time to tumor progression, progression-free survival, and overall survival, in these patients.
To explore potential correlations between clinical outcome and biomarkers of interest, including S6 protein overexpression and/or other mTOR-related proteins in blood and tumor biopsy samples from these patients.

OUTLINE: This is a multicenter study.

Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Blood, serum, and tumor tissue samples are collected for biomarker analysis.

After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months thereafter.

Enrollment

49 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of adenocarcinoma of the upper gastrointestinal tract
Metastatic or unresectable disease
Received 1-2 prior chemotherapy or biological therapy regimens for unresectable or metastatic disease
Measurable disease in ≥ 1 dimension by CT scan or MRI
Patients whose only measurable lesion is a metastatic lymph node are eligible provided they have permission from the principal investigator
ECOG performance status 0-1
Life expectancy > 3 months
ANC ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 9 g/dL
Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
AST and ALT ≤ 2.5 times ULN (≤ 5.0 times ULN if there is liver metastasis)
Creatinine clearance > 60 mL/min
Fasting serum cholesterol < 300 mg/dL or < 7.75 mmol/L*
Fasting triglycerides < 2.5 times ULN*
INR ≤ 3.5 (for patients on warfarin)
Negative pregnancy test
Fertile patients must use effective contraception during and for ≥ 4 months after completion of study treatment (oral, implantable, or injectable contraceptives are not considered effective contraception for this study)
More than 30 days since prior chemotherapy, surgery, radiotherapy, or investigational agents

Exclusion criteria

uncontrolled diabetes mellitus, defined as fasting serum glucose > 1.5 times ULN
severely impaired lung function
known HV infection
active, bleeding diathesis
unstable angina pectoris, symptomatic congestive heart failure, or myocardial infarction within the past 6 months
serious uncontrolled cardiac arrhythmia
active or uncontrolled infection requiring parenteral antimicrobials
known liver disease (e.g., cirrhosis, chronic active hepatitis, or chronic persistent hepatitis)
inability to swallow, impaired gastrointestinal (GI) function, or GI disease (e.g., ulcerative colitis, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) that would significantly alter the absorption of study drugs or preclude the use of oral medications
other malignancy within the past 5 years except for nonmelanoma skin cancer or cervical carcinoma in situ
known hypersensitivity to everolimus, sirolimus, or temsirolimus or to their excipients
other medical conditions that, in the opinion of the investigator, would preclude study participation
prior mTOR inhibitors (e.g., rapamycin, CCI-779)
concurrent chronic treatment with steroids or another immunosuppressive agent
concurrent prophylactic use of hematopoietic growth factors
concurrent anticancer agents or therapy (including radiotherapy)
other concurrent experimental agents
concurrent strong inhibitors or inducers of the isoenzyme CYP3A4